IP Verse

Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells - EP3105317

The patent EP3105317 was granted to Cellectis on Sep 19, 2018. The application was originally filed on Feb 13, 2015 under application number EP15706399A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3105317

CELLECTIS
Application Number
EP15706399A
Filing Date
Feb 13, 2015
Status
Opposition Rejected
Feb 4, 2022
Grant Date
Sep 19, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEJun 19, 2019ADMISSIBLE
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBJun 19, 2019ADMISSIBLE

Patent Citations (44) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONFR901228
DESCRIPTIONUS2006121005
DESCRIPTIONUS4683195
DESCRIPTIONUS5858358
DESCRIPTIONUS5883223
DESCRIPTIONUS6010613
DESCRIPTIONUS6352694
DESCRIPTIONUS6534055
DESCRIPTIONUS6642043
DESCRIPTIONUS6692964
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONUS8263746
DESCRIPTIONWO2004083379
DESCRIPTIONWO2006097854
DESCRIPTIONWO2008047242
DESCRIPTIONWO2012012667
DESCRIPTIONWO2012138927
DESCRIPTIONWO2013153391
DESCRIPTIONWO2013176915
DESCRIPTIONWO2014011988
DESCRIPTIONWO2014018601
DESCRIPTIONWO2014039523
DESCRIPTIONWO9424277
INTERNATIONAL-SEARCH-REPORTUS2013315884
INTERNATIONAL-SEARCH-REPORTWO2013074916
OPPOSITIONEP2039766
OPPOSITIONUS2007036773
OPPOSITIONUS2012060230
OPPOSITIONUS2013315884
OPPOSITIONUS2013323214
OPPOSITIONWO2012145384
OPPOSITIONWO2013074916
OPPOSITIONWO2013176915
OPPOSITIONWO2014191128

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- BRENNER et al., "Adoptive T cell therapy of cancer", Current Opinion in Immunology, (20100000), vol. 22, pages 251 - 257, XP027020482-
OPPOSITION- DOTTI et al., "Fas knockdown mediated by siRNA in EBV-specific cytotoxic T-Lymphocytes (CTL) Reduces Their Sensitivity to Fas/FasL-Induced Apoptosis", MOLECULAR THERAPY, (20050500), vol. 11, no. 1, pages S311 - S312, XP005016140-
OPPOSITION- KELLAR et al., "CD56-Specific Cells Can Distinguish between Allogeneic and Autologous CD56+ Targets", Molecular Therapy, (20110501), vol. 19, no. 1, pages S192 - S193, XP055563574-
OPPOSITION- MIHARA et al., "Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma", J Immunother, (20090901), vol. 32, no. 7, pages 737 - 43, XP009132660-
OPPOSITION- MIHARA et al., "Activated T- cell mediated immunotherapy with a chimeric receptor against CD 38 in B- cell non-Hodgkin lymphoma", Journal of Immunotherapy, (20090901), vol. 32, no. 7, pages 737 - 743, XP009132660-
OPPOSITION- BLITZ et al., "Biallelic genome modification in F0 Xenopus tropicalis embryos using the CRISPR/Cas system", Genesis, (20130000), vol. 51, pages 827 - 834, XP055598238
OPPOSITION- COLLINS et al., "Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS 1 ligation: evidence for augmented NK cell function complementing ADCC", Cancer Immunology, Immunotherapy, NIH Author Manuscript, (20140817), pages 1 - 15, XP055619300
OPPOSITION- HAGA et al., "Permanent, lowered HLA Class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes", Transplantation Proceedings, (20060000), vol. 38, pages 3184 - 3188, XP025007998
OPPOSITION- KIM et al., "Development of novel avenues to overcome challenges facing CAR T cells", Translational Research, (20170530), vol. 187, pages 22 - 31, XP085184178
OPPOSITION- BHATTACHARYYA et al., "T-cell immunotherapy with a chimeric receptor against CD3 8 1s effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1", Blood Cancer J, (20120600), vol. 2, no. 6, page e75, XP055138165
OPPOSITION- MIHARA et al., "T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells", Leukemia, (20110812), vol. 26, no. 2, doi:10.1038/leu.2011.205, pages 365 - 367, XP055138116
OPPOSITION- MIHARA et al., "T- cell immunotherapy with a chimeric receptor against CD 38 is effective in eliminating myeloma cells", Leukemia, (20110812), vol. 26, no. 2, pages 365 - 367, XP055138116
OPPOSITION- PULE et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma", Nature Medicine,, (20081100), vol. 14, no. 11, pages 1264 - 1270, XP055021755
OPPOSITION- PROVASI et al., "Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer", Nature Medicine, (20120401), vol. 18, no. 5, pages 807 - 817, XP055181611
OPPOSITION- KERSHAW et al., "Gene-engineered T cells for cancer therapy", Nature Reviews, (20130000), vol. 13, pages 525 - 541, XP055185130
OPPOSITION- HAN et al., "Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression", Nature Communications, (20180000), vol. 9, no. 468, pages 1 - 13, XP055536582
OPPOSITION- PARK et al., "Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma", Molecular Therapy, (20070400), vol. 15, no. 4, pages 825 - 833, XP055021897
OPPOSITION- MIHARA et al., "Synergistic and persistent effect of T‐cell immunotherapy with anti‐CD19 or anti‐CD38 chimeric receptor in conjunction with rituximab on B‐cell non‐Hodgkin lymphoma", Brit J Haematol, (20101000), vol. 151, no. 1, pages 37 - 46, XP055086001
OPPOSITION- WOOD et al., "Targeted genome editing across species using ZFNs and TALENs", Science, NIH Author Manuscript, (20110715), vol. 333, no. 6040, pages 1 - 4, XP055619322
OPPOSITION- SUN et al., "Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies", Journal of Immunology Research, (20180417), vol. 2018, pages 1 - 10, XP055619319
OPPOSITION- OKAMOTO et al., "Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR", Cancer Res., (20091201), vol. 69, no. 23, pages 9003 - 9011, XP002754590
OPPOSITION- MAUS et al., "CARTs on the road for myeloma", Clin. Cancer Res., (20140801), vol. 20, no. 15, pages 3899 - 3901, XP055160598
OPPOSITION- SADELAIN et al., "The Basic Principles of Chimeric Antigen Receptor Design", (20130000), doi:10.1158/2159-8290.CD-12-0548, pages 388 - 398, XP055287277
OPPOSITION- SADELAIN et al., "The basic principles of chimeric antigen receptor design", Cancer Discovery, (20130401), vol. 3, no. 4, pages 388 - 398, XP055287277
OPPOSITION- TANIGUCHI et al., Blood, (20070915), vol. 110, no. 6, pages 2020 - 2023, XP055616816
OPPOSITION- TORIKAI et al., "A foundation for universal T- cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", Blood, (20120614), vol. 119, no. 24, pages 5697 - 5705, XP055071623
OPPOSITION- TORIKAI et al., "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, (20120614), vol. 119, no. 24, pages 5697 - 5705, XP055071623
OPPOSITION- TORIKAI et al., "Toward eliminating HLA class I expression to generate universal cells from allogenic donors", Blood, (20130822), vol. 122, no. 8, pages 1341 - 1349, XP002719612
OPPOSITION- CASUCCI et al., "CD 44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma", Blood, (20131114), vol. 122, no. 20, pages 3461 - 3472, XP002791480
OPPOSITION- MAMONKIN et al., "A T- cell -directed chimeric antigen receptor for the selective treatment of T- cell malignancies", Blood, (20150820), vol. 126, no. 8, pages 983 - 992, XP055325148
OPPOSITION- MANNIOUI et al., "Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells", JOURNAL FOR IMMUNOTHERAPY OF CANCER, (20131107), vol. 1, no. Suppl 1, page P34, XP021167243
OPPOSITION- MANNIOUI et al., "Treatment of B cells malignancies with anti- CD 19 CAR+, TCR-, CD 52- allogenic T cells", Journal for Immunotherapy of Cancer, (20131107), vol. 1, no. 1, page P34, XP021167243
OPPOSITION- LAMERS et al., "Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience", (20060501), vol. 24, no. 13, pages e20 - e22, XP055619315
OPPOSITION- SZWEYKOWSKA-KULINSKA et al., "RNA interference and its role in the regulation of eukaryotic expression", ACTA BIOCHIMICA POLONICA, (20030000), vol. 50, no. 1, pages 217 - 229, XP055619325
OPPOSITION- Sung Yoon Choo, "The HLA system: genetics, immunology , clinical testing and clinical implications", Yonsei Medical Journal, (20070000), vol. 48, no. 1, pages 11 - 23, XP055619307
OPPOSITION- LLOYD et al., "Lipopolysaccharide induces IFN-γ production in human NK cells", Frontiers Immunol, (20130100), vol. 4, pages 1 - 7, XP055614763
OPPOSITION- LLOYD et al., "Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies", Frontiers in Immunology, (20130000), vol. 4, XP055110101

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents